Pharma BD Deal Intelligence
GlaxoSmithKline's $1B tender to lift its stake in the Indian subsidiary from 50.7% to 75% has been a slow-burn disappointment: 12 years on, the stock sits below the ₹3,100 entry price, squeezed by Indian price controls (Ceftum cut ~60% under 2022's essential-medicines list), though FY26 shows a 10% profit recovery.
Glaxo investing about $1 billion to raise its stake in its Indian drug unit to 75%, offering Rs 3,100 a share, a 26% premium over the prior close.
GlaxoSmithKline takes firmer control over its Indian operation, with the deal underscoring the British drugmaker's drive to deepen its presence in emerging…
GSK confirmed open offer success, lifting stake to 75% — the maximum allowed under Indian listing rules — for total consideration of approximately…
Source summaries from our enrichment pipeline; follow links for originals.
All 7 sources with sentiment breakdown →
GSK launched voluntary open offer at INR 3,100/share (26% premium) to raise stake in GSK Pharmaceuticals India from 50.7% to 75% — total cost ~£629M (~$1.02B).
Assessment window: 5yr post-close.
This deal was a corporate-control transaction rather than a single-disease asset purchase. GSK's Indian listed subsidiary commercializes a multi-therapy prescription portfolio across respiratory, anti-infective, dermatology, cardiovascular, and vaccine franchises. The India market is one of the world's largest by volume, with branded generics dominating and price controls compressing margins for premium-priced multinationals.
GSK's December 2013 voluntary open offer to raise its stake in GlaxoSmithKline Pharmaceuticals Limited (India) from 50.7% to 75% was a strategic emerging-markets bet rather than a product-specific transaction. At the time, multinational pharma in India faced competitive pressure from domestic generics players (Sun Pharma, Cipla, Dr Reddy's, Lupin) and rising regulatory scrutiny under the new National Pharmaceutical Pricing Policy, which compressed prices on essential medicines and disproportionately impacted GSK's premium-branded portfolio. The INR 3,100/share price represented a 26% premium and earned mixed analyst takes: Angel Broking saw it as commitment to a strategically important market, while institutional investors flagged the price as unattractive given a 20% pre-offer rally. The deal completed March 2014 oversubscribed, lifting GSK to 75% — the new maximum permitted under Indian listing rules requiring 25% public float. Comparable peer moves around the same period (Sanofi's 60% stake in Shantha, Pfizer's continued India presence, Abbott's $3.7B Piramal acquisition in 2010) framed the transaction as part of a broader multinational consolidation push in Indian pharma.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| GlaxoSmithKline plc / GlaxoSmithKline Pharmaceuticals Limited (India) — minority stake increase (this deal) | 2013 | $1.0B | 43 |
| GlaxoSmithKline plc / Theravance, Inc. | 2012 | $213M | 82 |
| GlaxoSmithKline plc / Tesaro Inc. | 2018 | $5.1B | 79 |
| GlaxoSmithKline plc / Pfizer Inc. (Consumer Healthcare Division) | 2018 | $12.7B | 76 |
| GlaxoSmithKline plc / Novartis Consumer Healthcare JV | 2018 | $13.0B | 74 |
| GlaxoSmithKline plc / ID Biomedical Corporation | 2005 | $1.4B | 64 |
| GlaxoSmithKline plc / Vir Biotechnology Inc. | 2020 | $595M | 51 |
← Browse all deals · How we score deals
More: 2013 deals · GlaxoSmithKline plc deals · Other deals